Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia

Dan Douer Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Kristy Watkins Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Alexandra M. Levine Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Jane M. Weiss ILEX Oncology Inc., San Antonio, TX, USA

Lynette C. Marshall ILEX Oncology Inc., San Antonio, TX, USA

Adam R. Craig ILEX Oncology Inc., San Antonio, TX, USA

Abstract

Refractory AML patients have a very poor prognosis. Therefore, rationally designed new therapies, including clofarabine, are being investigated as potential treatments for this patient population. This is a case report of a patient with primary refractory AML who was treated with clofarabine and achieved a complete response.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia

Information for

Open access

Opportunities

Help and information

Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature